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Summary
Major depressive disorder is a highly prevalent condition for 
which the treatment of ﬁ rst resort is often a selective serotonin 
reuptake inhibitor (SSRI). There is a paucity of evidence about 
the long-term effects of SSRI use and unpleasant side effects 
of SSRIs are common. As a result, interest has increased 
in new and nonpharmacological treatments for depression. 
Various forms of electrical and magnetic stimulation have 
been explored as possible interventions. In this study the 
authors compare the effects of transcranial direct current 
stimulation (tDCS) to those of escitalopram for the treatment 
of unipolar depressive disorder.
tDCS is a form of electrical stimulation that entails the 
application of electrodes to a participant’s scalp and the 
passing of a direct electrical current between them. tDCS 
does not cause action potentials, as are typically associated 
with most forms of transcranial magnetic stimulation (TMS), 
but has been shown to temporarily alter the resting potential 
of the membranes of affected neurons. Physiological studies 
have shown that neurons in proximity to the positive electrode 
(anode) have a raised resting potential, and thus require a 
lower level of dendritic input to generate an action potential. 
The converse applies to neurons close to the negative 
electrode (cathode), which are temporarily inhibited. As the 
authors note, tDCS is less associated with major adverse 
side effects (e.g. seizures) than TMS and therefore may be 
more acceptable as a clinical intervention. It must be noted, 
however, that tDCS has been associated with minor adverse 
events (e.g. skin reddening, pain at the site of application, 
headaches) therefore its use is not wholly without issue.
In a previous study,1 the authors compared the effects of 
tDCS and a SSRI (sertraline) to those of sertraline alone 
in the treatment of depression. They showed that the 
combination of stimulation and sertraline was superior 
to that of sertraline alone. The current study builds upon 
previous work by making a comparison between the effects 
of tDCS, a SSRI (escitalopram), and placebo. The authors 
investigated the hypothesis that tDCS would be non-inferior 
to escitalopram in the reduction of participants’ scores on a 
standard depression index (the 17-item Hamilton Depression 
Rating Scale (HDRS-17)).
A total of 245 patients were assigned to one of three treatment 
groups. The ﬁ rst group received tDCS and a placebo tablet, 
the second received sham tDCS and escitalopram, and the 
third received sham tDCS and a placebo tablet. For admission 
to the study, participants were required to register moderate 
or severe depression on the HDRS-17 (indicated by a score of 
17 or above out of a maximum of 52; a score of 24 or above 
indicating severe depression). In addition, participants were 
required to be naïve to tDCS and escitalopram (though not to 
all SSRIs). Participants taking antidepressants were required 
to undergo a wash-out period prior to study commencement. 
They were required to reduce any use of benzodiazepines 
to no more than the equivalent of 20 mg diazepam per day 
by the start of the study. Slightly over one quarter of the 
participants used benzodiazepines during the study.
The tDCS protocol consisted of the application of two 25 
cm2 electrodes to the participants’ scalps with a current 
of 2 mA being applied for 30 min during each session. The 
anode and cathode were placed over the participants’ left and 
right dorsolateral prefrontal cortices (DLPFC), respectively 
(these sites chosen as previous studies have shown that left 
DLPFC hypoactivity and right DLPFC hyperactivity have been 
associated with major depressive disorder2). Participants 
attended tDCS sessions for 15 consecutive week-days, 
followed by a weekly session for the next 7 weeks. In the 
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case of sham tDCS, the participants underwent the same 
protocol with the exception that current was turned off after 
30 s by the tDCS device. tDCS is most noticeable (and most 
unpleasant) when there is a change in the current that is 
applied to the skin. As such, it is invariably the case that the 
application of tDCS will include a fade-in period at the start 
of stimulation: this will entail the gradual, steady increase 
of current to the intended level. This fading-in minimises the 
sensations (generally a tingling or mild burning) associated 
with tDCS. A similar fade-out period is used at the end of 
stimulation. Given that the sensations associated with tDCS 
are at their strongest during fade-in and out, these periods 
are used to blind participants to the nature of the stimulation 
that they are receiving. In this study, participants receiving 
sham tDCS experienced fade-in, 30 s of stimulation and fade-
out (followed by 30 min of no stimulation), thus giving them a 
comparable experience to those receiving active tDCS.
Participants received either a placebo tablet or 10 mg 
escitalopram daily for the ﬁ rst 3 weeks of the trial followed 
by 20 mg daily for the remaining 7 weeks. 
The authors observed that the participants’ level of 
depression (as measured by the HDRS-17) was reduced in 
all groups at the end of 10 weeks, with the decrease being 
largest in the escitalopram group (11.3 +/- 6.5), followed by 
the tDCS group (9.0 +/- 7.1) and then placebo (5.8 +/- 7.9). 
The authors speciﬁ ed that to claim non-inferiority of tDCS to 
escitalopram they would require the lower boundary of the 
conﬁ dence interval (on a modiﬁ ed t-test for non-inferiority) 
of the effects of tDCS to be at least 50% of the difference 
between the escitalopram and placebo groups. The effects 
of tDCS did not meet this criterion and therefore, while tDCS 
was superior to placebo, non-inferiority to escitalopram could 
not be claimed. 
Participants in the active tDCS group were signiﬁ cantly more 
likely to report itching, tingling, skin redness, tinnitus and 
nervousness than the other groups. Two of 91 participants 
in the tDCS group had new-onset mania (as measured on the 
Young Mania Rating Scale). Participants in the escitalopram 
were significantly more likely to report sleepiness and 
constipation than those in other groups. The authors report 
that participants were able to guess their trial-group allocation 
with regard to escitalopram, but not with regard to tDCS.
Opinion
The use of SSRIs for the treatment of depression has become 
so commonplace that members of this family have appeared 
on the list of drugs most prescribed in the UK.3 This is true in 
many other countries. Patients have expressed concern about 
the disruptive side effects that are commonly experienced, 
including changes to sleeping patterns, appetite and sexual 
function. Of additional concern to patients and physicians is 
a lack of a clear understanding of the effects of long-term 
use. These concerns have driven efforts towards ‘cleaner’ 
versions of SSRI medication (including escitalopram, a 
successor of citalopram) and investigations of alternative 
treatments. The most commonly considered alternatives have 
been forms of psychotherapy, which while appropriate for 
some cases of mild to moderate depression, have not proved 
effective for more serious cases. As such, there remains a 
strong motivation to continue the search for other treatments.
In recent years greater consideration has been given to forms 
of magnetic and electrical stimulation as interventions for 
psychological conditions. Psychological electromedicine has a 
long (and not always glorious) history having been used in the 
form of electroshock therapy and more recently deep neural 
stimulation for intractable depression. As the technology 
available for the delivery of brain stimulation has improved, 
the possibility of making better targeted and less dramatic 
interventions has increased. Investigations have been focused 
on the use of TMS and more recently transcranial electrical 
stimulation as interventions for a range of conditions. 
Evidence has been accumulated that suggests TMS can be 
effective in depression, post-traumatic stress disorder and in 
treating auditory verbal hallucinations. Despite the discomfort 
experienced by patients, recommendations have been made 
for the inclusion of TMS in the psychiatrist’s armamentarium. 
There is less experience of the use of transcranial electrical 
stimulation and therefore the examination of its use by the 
present study’s authors is merited. 
The stimulation used in this case was transcranial direct 
current stimulation (tDCS), which is generally experienced 
by subjects as mildly unpleasant rather than painful or 
distressing. The adverse effects of tDCS are most commonly 
a burning or tingling at the scalp around the edges of the 
contact pads used to deliver the current. Less common 
effects are headaches and dizziness. The authors’ note of 
two new-onset cases of mania is uncommon, but is seemingly 
becoming less so with six groups reporting cases of mania 
or hypomania after the application of tDCS since 2010.4 
The increased incidence of post-tDCS mania is perhaps 
understandable for both the increased interest in the use of 
tDCS as a clinical tool for the treatment of mood disorder and 
the challenges presented in titrating the dose of stimulation 
received by patients. One might also wonder whether 
tDCS might unmask bipolar disease in patients previously 
diagnosed with unipolar depression.
Examining the ﬁ rst point, there is a growing amount of 
evidence of the asymmetrical contributions of left- and right-
dorsolateral prefrontal cortex to mood regulation. Given 
that these regions are located on ‘stimulatable’ surfaces 
of the brain and that tDCS has an opposite effect on brain 
tissue at its positive and negative electrodes (excitatory 
at the anode and inhibitory at the cathode), it is clear why 
the potential of tDCS to rebalance the activity of these 
regions would be of interest to researchers and clinicians. 
Repeated sessions of tDCS have been shown to promote 
‘conditioning’ changes in brain tissue (i.e. changes that 
last longer than the duration of stimulation) and therefore 
offer the possibility of therapeutically altering and then 
maintaining brain activity in a manner similar to that offered 
by pharmacological interventions.
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With regard to the delivery of a ‘dose’ of tDCS, we should 
consider the mechanism by which tDCS is delivered to brain 
tissue. Physiological studies have demonstrated that applying 
a current to neurons can alter their membrane resting 
potential and therefore temporarily adjust the level of dendritic 
input that is required to generate an action potential. It must 
be noted, however, that to reach brain tissue the current 
travelling between the stimulator pads placed in contact with 
the scalp must ﬁ rst pass through the skull, the meninges and 
the highly conductive cerebrospinal ﬂ uid. The conductivity of 
the cerebrospinal ﬂ uid and individual differences in subject 
anatomy mean that it is highly challenging to determine the 
level of stimulation delivered to a brain area of interest. In 
preclinical research these challenges have been approached 
through the use of neuroimaging to enable researchers 
to ‘see’ the structure of brain tissue beneath proposed 
stimulation sites,5 and studies that have mathematically 
modelled likely current flows.6 These approaches are 
expensive in terms of both time and resources and have not 
been widely applied to clinical studies.
This study gives an example of the challenges associated 
with blinding human subjects to their treatment group. It 
is interesting to note that the authors were successful in 
concealing the type of tDCS received (sham or verum), but 
were unable to prevent participants from determining they 
were receiving escitalopram or placebo. Creating a sham 
stimulation condition has been a challenge that has not 
always been successfully addressed: in TMS studies, the 
presence or absence of a ‘tapping’ sensation at the scalp 
or muscle activations have tended to inform participants 
of the treatment received. Progress has been made in 
tDCS blinding given that the sensations experienced 
tend to be most noticeable when the level of stimulation 
changes rather than when a participant receives a steady 
level of stimulation. This enables experimenters to blind 
participants by having ramp-up and ramp-down periods at 
either side of a period of steady or no stimulation. This has 
become a de facto standard and has proved effective, as 
was the case in this study. 
Blinding a psychopharmacological intervention is challenging 
where participants are not naïve to the effects of this or 
similar medicines. The side-effects of initiating escitalopram 
usage are well-documented (and are essentially the same 
as those associated with other SSRIs: anxiety, nausea, 
restlessness, headaches etc.). In this study the participants 
were required to be naïve to escitalopram, but not other 
SSRIs. It is probable that this experience played a role in 
enabling the participants to infer their treatment group. 
It would be informative to determine whether blinding to 
psychopharmacological interventions requires treatment 
naïvety to be of a broader scope.
It is interesting that around one third of the participants in two 
groups and one ﬁ fth in the other were using benzodiazepine 
during the study. Anxiety disorders are commonly comorbid 
with depression therefore the use of benzodiazepine by this 
cohort is not particularly surprising, but (as noted by the 
author previously7) this family of medications can alter the 
effects of tDCS. Brunoni found that benzodiazepine reduced 
the effectiveness of tDCS, therefore removing this factor from 
future studies may give a clearer indication of whether tDCS 
is non-inferior to escitalopram in the treatment of depression. 
In conclusion, the authors have presented further evidence of 
the potential efﬁ cacy of electrical stimulation in the treatment 
of depression, shown that blinding of electrical stimulation 
can be effective, and that the stimulation is largely well-
tolerated. The authors have also highlighted that challenges 
still remain for the clinical application of stimulation given the 
uncertainties that still exist in titrating the dose of stimulation 
and the possibility of adverse side effects. 
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